Gilead Sciences, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $4.63B | $13.50B | $18.11B | $12.10B | $3.08B | $2.59B | $2.80B | $2.90B |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $233.0M | $177.0M | $161.0M | $125.0M | $103.0M | $83.0M | $72.2M | $67.2M |
| Amortization | — | — | — | — | — | $63.3M | $69.6M | $59.9M |
| Stock-Based Compensation | $638.0M | $380.0M | $382.0M | $360.0M | $252.0M | $209.0M | $192.4M | $200.0M |
| Net Cash from Operating Activities | $11.90B | $17.05B | $21.25B | $12.82B | $3.11B | $3.20B | $3.64B | $2.83B |
| Investing Activities | ||||||||
| Capital Expenditures | $590.0M | $748.0M | $747.0M | $557.0M | $134.0M | $397.0M | $131.9M | $61.9M |
| Business Acquisitions | $10.43B | $0 | $0 | $0 | $379.0M | $10.75B | $588.6M | $91.0M |
| Net Cash from Investing Activities | $-16.07B | $-11.99B | $-12.48B | $-1.82B | $-254.0M | $-11.85B | $3.59B | $-1.94B |
| Financing Activities | ||||||||
| Dividends Paid | $2.73B | $2.46B | $1.87B | $0 | $0 | — | — | — |
| Stock Repurchases | $954.0M | $11.00B | $10.00B | $5.35B | $582.0M | $667.0M | $2.38B | $4.02B |
| Net Cash from Financing Activities | $3.39B | $-9.73B | $-5.88B | $-3.03B | $-2.54B | $563.0M | $1.76B | $-1.34B |
| Net Change in Cash | $-641.0M | $-4.62B | $2.82B | $7.91B | $309.0M | $-8.08B | $8.98B | $-365.1M |
| Free Cash Flow | $11.31B | $16.30B | $20.50B | $12.26B | $2.97B | $2.80B | $3.51B | $2.77B |